The Effect of intravenous Ascorbic acid combined with intravenous tranexamic acid in Anemia of Hemodialysis patients ; A Randomized Controlled Trial.

Phase 1

Recruiting

• Conditions: Hemodialysis patients which has Anemia of inflammation; Intravenous Ascorbic acid, Intravenous tranexamic acid, Anemia in hemodialysis patients

• Registration Number: TCTR20240512004
• Lead Sponsor: Buriram Hostpital, Thailand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-12
• Last Update Posted: 19 August 2024
• Study Completion: 2025-05-27

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Kidney failure patients undergoing hemodialysis treatment with hemodialysis who have anemia from inflammatory processes in the body with a hemoglobin level less than or equal to 11 g/dl, a serum ferritin level greater than 800 ng/ml, and a serum transferrin saturation greater than or equal to 40%.

Exclusion Criteria

1) Patients with end stage kidney disease receiving kidney replacement therapy with hemodialysis who have a history of epilepsy. or have had a history of brain surgery
2) Patients with urinary tract stone problems
3) Patients who are allergic to vitamin C injectable form and allergic to tranexamic acid.
4) Patients who have received iron injections within the past 2 months.
5) Patients who refuse to participate in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum iron, Feritin, Total iron binding capacity, Hematocirt 6 months micromol/L, %Tranferin saturation

Secondary Outcome Measures

Name	Time	Method
intact Parathyroid hormone, C-reactive protein, Erythrocyte Sedimentation rate, uric acid 6 months pg/ml, mg/L, mm/h, mg/dl(micromol/L)